Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
Department of Biomedical Laboratory Science, Konyang University, Daejeon 35365, Korea.
Molecules. 2018 Apr 4;23(4):830. doi: 10.3390/molecules23040830.
Aptamers are single-stranded oligonucleotides that specifically bind and interact with their corresponding targets, including proteins and cells, through unique three-dimensional structures. Numerous aptamers have been developed to target cancer biomarkers with high specificity and affinity, and some are employed as versatile guiding ligands for cancer-specific drug delivery and anti-cancer therapeutics. In this review, we list the aptamers that target tumor surface biomarkers and summarize the representative applications of aptamers as agonists and antagonists that activate anti-cancer and inactivate pro-cancer biomarkers, respectively. In addition, we describe applications of aptamer-drug or aptamer-oligonucleotide conjugates that can deliver therapeutic agents, including small interfering RNAs, micro RNAs, short hairpin RNAs, and chemotherapeutic molecules, to cancer cells. Moreover, we provide examples of aptamer- conjugated nano-vehicles, in which cancer-targeting oligonucleotide aptamers are conjugated with nano-vehicles such as liposomes, micelles, polymeric nanoparticles, and quantum dots. Conjugation of aptamers with anti-cancer drugs and nano-vehicles will facilitate innovative applications of aptamer-based cancer therapeutics.
适体是单链寡核苷酸,通过独特的三维结构特异性结合并与相应的靶标(包括蛋白质和细胞)相互作用。已经开发出许多适体来靶向癌症生物标志物,具有高特异性和亲和力,有些适体可用作癌症特异性药物输送和抗癌治疗的多功能导向配体。在这篇综述中,我们列出了靶向肿瘤表面生物标志物的适体,并总结了适体作为激动剂和拮抗剂的代表性应用,分别激活抗癌和失活促癌生物标志物。此外,我们描述了适体-药物或适体-寡核苷酸缀合物的应用,这些缀合物可以将治疗剂(包括小干扰 RNA、微 RNA、短发夹 RNA 和化疗分子)递送到癌细胞中。此外,我们还提供了适体偶联纳米载体的示例,其中癌症靶向寡核苷酸适体与纳米载体(如脂质体、胶束、聚合物纳米颗粒和量子点)偶联。将适体与抗癌药物和纳米载体偶联将促进基于适体的癌症治疗的创新应用。